First Tracks Biotherapeutics, Inc. (TRAX) Stock

No profile data available.

About First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks Biotherapeutics, Inc. (TRAX) is a listed company, based in San Diego, United States, with about 104 full-time employees.

It reported revenue of $0 for fiscal year 2024, and net income of -$163.71 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.14 billion as of October 9, 2026.

Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.

Headquarters: San Diego, United States
Employees: 104
Exchange: NasdaqGS
Market cap: $1.14 billion (October 9, 2026)
Revenue (FY2024): $0

Frequently asked questions

What does First Tracks Biotherapeutics do?

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.

How much revenue does First Tracks Biotherapeutics make?

First Tracks Biotherapeutics reported $0 in revenue for fiscal year 2024. In Q2 2026 revenue was $0.

What is First Tracks Biotherapeutics's market cap?

$1.14 billion as of October 9, 2026.

Industry and sector

Stock screener Search all stocks

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Metric	Value	Period
Total Revenue	9999999999999	FY2099
Net Income	-8888888888	FY2099
Earnings Per Share	123.456789	FY2099
Gross Profit	7777777777	FY2099
Operating Income	6666666666	FY2099